Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease

Pharmacological Research

Volumn 125, Issue , 2017, Pages 57-71

  Ferrario, Carlos M ^a   Mullick, Adam E ^b  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Angiotensin (1 12); Angiotensin (1 7); Heart failure; Hypertension

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTISENSE OLIGONUCLEOTIDE; CANDESARTAN; CANDESARTAN HEXETIL; CANDOXATRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALKIREN; ENKEPHALINASE INHIBITOR; EPLERENONE; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; MINERALOCORTICOID ANTAGONIST; OSILODROSTAT; PERINDOPRIL; PERINDOPRIL TERT BUTYLAMINE; PLACEBO; QUINAPRIL; REMIKIREN; RENIN INHIBITOR; SACUBITRIL PLUS VALSARTAN; SINORPHAN; SPIRONOLACTONE; TELMISARTAN; UNINDEXED DRUG; VALSARTAN; ZANKIREN; ALDOSTERONE; ANGIOTENSIN II; RENIN;

ACNE; ADD ON THERAPY; AGEUSIA; ALLERGIC REACTION; ALOPECIA; AMENORRHEA; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; APLASTIC ANEMIA; BACKACHE; BIOTRANSFORMATION; BREAST HYPERTROPHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COUGHING; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; EDEMA; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FAINTNESS; GENDER DYSPHORIA; HEADACHE; HEART FAILURE; HEART INFARCTION; HIRSUTISM; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LEG PAIN; LIVER DYSFUNCTION; METALLIC TASTE; NONHUMAN; NOSE OBSTRUCTION; PANCREATITIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THORAX PAIN; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; WEAKNESS; ANIMAL; DRUG EFFECT; METABOLISM;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 85020137118     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.05.020     Document Type: Review

References (275)

1. Roth, G.A., Forouzanfar, M.H., Moran, A.E., Barber, R., Nguyen, G., Feigin, V.L., Naghavi, M., Mensah, G.A., Murray, C.J., Demographic and epidemiologic drivers of global cardiovascular mortality. N. Engl. J. Med. 372:14 (2015), 1333–1341.
2. Case, A., Deaton, A., Rising morbidity and mortality in midlife among white non-hispanic Americans in the 21st century. Proc. Natl. Acad. Sci. U. S. A. 112:49 (2015), 15078–15083.
3. Benjamin, E.J., Blaha, M.J., Chiuve, S.E., Cushman, M., Das, S.R., Deo, R., de Ferranti, S.D., Floyd, J., Fornage, M., Gillespie, C., Isasi, C.R., Jimenez, M.C., Jordan, L.C., Judd, S.E., Lackland, D., Lichtman, J.H., Lisabeth, L., Liu, S., Longenecker, C.T., Mackey, R.H., Matsushita, K., Mozaffarian, D., Mussolino, M.E., Nasir, K., Neumar, R.W., Palaniappan, L., Pandey, D.K., Thiagarajan, R.R., Reeves, M.J., Ritchey, M., Rodriguez, C.J., Roth, G.A., Rosamond, W.D., Sasson, C., Towfighi, A., Tsao, C.W., Turner, M.B., Virani, S.S., Voeks, J.H., Willey, J.Z., Wilkins, J.T., Wu, J.H., Alger, H.M., Wong, S.S., Muntner, P.C., American heart association statistics, S. stroke statistics, heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135 (2017), e146–e603.
4. Timmermans, P.B., Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens. Res. 22:2 (1999), 147–153.
5. Timmermans, P.B., Duncia, J.V., Carini, D.J., Chiu, A.T., Wong, P.C., Wexler, R.R., Smith, R.D., Discovery of losartan, the first angiotensin II receptor antagonist. J. Hum. Hypertens. 9:Suppl. 5 (1995), S3–18.
6. Azizi, M., Menard, J., Renin inhibitors and cardiovascular and renal protection: an endless quest?. Cardiovasc. Drugs Ther. 27:2 (2013), 145–153.
7. Gheorghiade, M., Bohm, M., Greene, S.J., Fonarow, G.C., Lewis, E.F., Zannad, F., Solomon, S.D., Baschiera, F., Botha, J., Hua, T.A., Gimpelewicz, C.R., Jaumont, X., Lesogor, A., Maggioni, A.P., Investigators, A., Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309:11 (2013), 1125–1135.
8. McMurray, J.J., Krum, H., Abraham, W.T., Dickstein, K., Kober, L.V., Desai, A.S., Solomon, S.D., Greenlaw, N., Ali, M.A., Chiang, Y., Shao, Q., Tarnesby, G., Massie, B.M., Investigators, A.C., Enalapril, or aliskiren and enalapril in heart failure. N. Engl. J. Med. 374:16 (2016), 1521–1532.
9. McMurray, J.J., Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur. J. Heart Fail. 17:3 (2015), 242–247.
10. Gavras, H., Brunner, H.R., Laragh, J.H., Gavras, I., Vukovich, R.A., The use of angiotensin-converting enzyme inhibitor in the diagnosis and treatment of hypertension. Clin. Sci. Mol. Med.(Suppl. 2), 1975, 57s–60s.
11. Nussberger, J., Wuerzner, G., Jensen, C., Brunner, H.R., Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 39:1 (2002), E1–8.
12. Ferrario, C.M., Schiffrin, E.L., Role of mineralocorticoid receptor antagonists in cardiovascular disease. Circ. Res. 116:1 (2015), 206–213.
13. Dell'Italia, L.J., Translational success stories: angiotensin receptor 1 antagonists in heart failure. Circ. Res. 109:4 (2011), 437–452.
14. Baker, W.L., Coleman, C.I., Kluger, J., Reinhart, K.M., Talati, R., Quercia, R., Phung, O.J., White, C.M., Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann. Intern. Med. 151:12 (2009), 861–871.
15. Bangalore, S., Fakheri, R., Wandel, S., Toklu, B., Wandel, J., Messerli, F.H., Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ, 356, 2017, j4.
16. Blacher, J., Evans, A., Arveiler, D., Amouyel, P., Ferrieres, J., Bingham, A., Yarnell, J., Haas, B., Montaye, M., Ruidavets, J.B., Ducimetiere, P., Group, P.S., Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study. J. Hum. Hypertens. 24:1 (2010), 19–26.
17. Brugts, J.J., van Vark, L., Akkerhuis, M., Bertrand, M., Fox, K., Mourad, J.J., Boersma, E., Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: a number-needed-to-treat analysis. Int. J. Cardiol. 181 (2015), 425–429.
18. Dusing, R., Mega clinical trials which have shaped the RAS intervention clinical practice. Ther. Adv. Cardiovasc. Dis. 10:3 (2016), 133–150.
19. Ferrario, C.M., Cardiac remodelling and RAS inhibition. Ther. Adv. Cardiovasc. Dis. 10:3 (2016), 162–171.
20. Ferrario, C.M., Ahmad, S., Varagic, J., Cheng, C.P., Groban, L., Wang, H., Collawn, J.F., Dell Italia, L.J., Intracrine angiotensin II functions originate from noncanonical pathways in the human heart. Am. J. Physiol. Heart Circ. Physiol. 311:2 (2016), H404–14.
21. Reyes, S., Varagic, J., Ahmad, S., VonCannon, J., Kon, N., Wang, H., Groban, L., Cheng, C.P., Ferrario, C.M., Novel cardiac intracrine mechanisms based on ang- (1–12)/chymase axis requires a revision of therapeutic approaches in human heart disease. Curr. Hypertens. Rep., 19, 2017, 16.
22. Drummer, O.H., Kourtis, S., Johnson, H., Formation of angiotensin II and other angiotensin peptides from des-leu 10-angiotensin I in rat lung and kidney. Biochem. Pharmacol. 37:22 (1988), 4327–4333.
23. Drummer, O.H., Kourtis, S., Johnson, H., Effect of chronic enalapril treatment on enzymes responsible for the catabolism of angiotensin I and formation of angiotensin II. Biochem. Pharmacol. 39:3 (1990), 513–518.
24. Ferrario, C.M., Brosnihan, K.B., Diz, D.I., Jaiswal, N., Khosla, M.C., Milsted, A., Tallant, E.A., Angiotensin-(1–7): a new hormone of the angiotensin system. Hypertension 18:Suppl. 5 (1991), III126–III133.
25. Ferrario, C.M., Chappell, M.C., Tallant, E.A., Brosnihan, K.B., Diz, D.I., Counterregulatory actions of angiotensin-(1–7). Hypertension 30:3 Pt 2 (1997), 535–541.
26. Jankowski, V., Vanholder, R., van der Giet, M., Tolle, M., Karadogan, S., Gobom, J., Furkert, J., Oksche, A., Krause, E., Tran, T.N., Tepel, M., Schuchardt, M., Schluter, H., Wiedon, A., Beyermann, M., Bader, M., Todiras, M., Zidek, W., Jankowski, J., Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler. Thromb Vasc. Biol. 27:2 (2007), 297–302.
27. Lautner, R.Q., Villela, D.C., Fraga-Silva, R.A., Silva, N., Verano-Braga, T., Costa-Fraga, F., Jankowski, J., Jankowski, V., Sousa, F., Alzamora, A., Soares, E., Barbosa, C., Kjeldsen, F., Oliveira, A., Braga, J., Savergnini, S., Maia, G., Peluso, A.B., Passos-Silva, D., Ferreira, A., Alves, F., Martins, A., Raizada, M., Paula, R., Motta-Santos, D., Klempin, F., Pimenta, A., Alenina, N., Sinisterra, R., Bader, M., Campagnole-Santos, M.J., Santos, R.A., Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ. Res. 112:8 (2013), 1104–1111.
28. Nagata, S., Hatakeyama, K., Asami, M., Tokashiki, M., Hibino, H., Nishiuchi, Y., Kuwasako, K., Kato, J., Asada, Y., Kitamura, K., Big angiotensin-25: a novel glycosylated angiotensin-related peptide isolated from human urine. Biochem. Biophys. Res. Commun. 441:4 (2013), 757–762.
29. Nagata, S., Kato, J., Sasaki, K., Minamino, N., Eto, T., Kitamura, K., Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem. Biophys. Res. Commun. 350:4 (2006), 1026–1031.
30. Gonzalez, A.A., Prieto, M.C., Roles of collecting duct renin and (pro)renin receptor in hypertension: mini review. Ther. Adv. Cardiovasc. Dis. 9:4 (2015), 191–200.
31. Navar, L.G., Kobori, H., Prieto, M.C., Gonzalez-Villalobos, R.A., Intratubular renin-angiotensin system in hypertension. Hypertension 57:3 (2011), 355–362.
32. Navar, L.G., Prieto, M.C., Satou, R., Kobori, H., Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. Curr. Opin. Pharmacol. 11:2 (2011), 180–186.
33. Ahmad, S., Varagic, J., Groban, L., Dell'Italia, L.J., Nagata, S., Kon, N.D., Ferrario, C.M., Angiotensin-(1–12): a chymase-mediated cellular angiotensin II substrate. Curr. Hypertens. Rep., 16(5), 2014, 429.
34. Trask, A.J., Jessup, J.A., Chappell, M.C., Ferrario, C.M., Angiotensin-(1–12) is an alternate substrate for angiotensin peptide production in the heart. Am. J. Physiol. Heart Circ. Physiol. 294:5 (2008), H2242–7.
35. Balcells, E., Meng, Q.C., Johnson, W.H. Jr., Oparil, S., Dell'Italia, L.J., Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am. J. Physiol. 273:4 Pt 2 (1997), H1769–H1774.
36. Dell'Italia, L.J., Husain, A., Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr. Opin. Cardiol. 17:4 (2002), 374–379.
37. Urata, H., Healy, B., Stewart, R.W., Bumpus, F.M., Husain, A., Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res. 66:4 (1990), 883–890.
38. Urata, H., Kinoshita, A., Misono, K.S., Bumpus, F.M., Husain, A., Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 265:36 (1990), 22348–22357.
39. Ferrario, C.M., Ahmad, S., Nagata, S., Simington, S.W., Varagic, J., Kon, N., Dell'italia, L.J., An evolving story of angiotensin-II-forming pathways in rodents and humans. Clin. Sci. (Lond.) 126:7 (2014), 461–469.
40. Ahmad, S., Varagic, J., VonCannon, J.L., Groban, L., Collawn, J.F., Dell'Italia, L.J., Ferrario, C.M., Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1–12) metabolizing enzyme. Biochem. Biophys. Res. Commun. 478:2 (2016), 559–564.
41. Jessup, J.A., Trask, A.J., Chappell, M.C., Nagata, S., Kato, J., Kitamura, K., Ferrario, C.M., Localization of the novel angiotensin peptide, angiotensin-(1–12), in heart and kidney of hypertensive and normotensive rats. Am. J. Physiol. Heart Circ. Physiol. 294:6 (2008), H2614–H2618.
42. Ferrario, C.M., VonCannon, J., Jiao, Y., Ahmad, S., Bader, M., Dell'Italia, L.J., Groban, L., Varagic, J., Cardiac angiotensin-(1–12) expression and systemic hypertension in rats expressing the human angiotensinogen gene. Am. J. Physiol. Heart Circ. Physiol. 310:8 (2016), H995–1002.
43. Nagata, S., Varagic, J., Kon, N.D., Wang, H., Groban, L., Simington, S.W., Ahmad, S., Dell'Italia, L.J., VonCannon, J.L., Deal, D., Ferrario, C.M., Differential expression of the angiotensin-(1–12)/chymase axis in human atrial tissue. Ther. Adv. Cardiovasc. Dis. 9:4 (2015), 168–180.
44. Arnold, A.C., Isa, K., Shaltout, H.A., Nautiyal, M., Ferrario, C.M., Chappell, M.C., Diz, D.I., Angiotensin-(1–12) requires angiotensin converting enzyme and AT1 receptors for cardiovascular actions within the solitary tract nucleus. Am. J. Physiol. Heart Circ. Physiol. 299:3 (2010), H763–H771.
45. Arakawa, H., Kawabe, K., Sapru, H.N., Angiotensin-(1–12) in the rostral ventrolateral medullary pressor area of the rat elicits sympathoexcitatory responses. Exp. Physiol. 98:1 (2013), 94–108.
46. De Mello, W.C., Dell'Itallia, L.J., Varagic, J., Ferrario, C.M., Intracellular angiotensin-(1–12) changes the electrical properties of intact cardiac muscle. Mol. Cell. Biochem. 422:1-2 (2016), 31–40.
47. Isa, K., Garcia-Espinosa, M.A., Arnold, A.C., Pirro, N.T., Tommasi, E.N., Ganten, D., Chappell, M.C., Ferrario, C.M., Diz, D.I., Chronic immunoneutralization of brain angiotensin-(1–12) lowers blood pressure in transgenic (mRen2)27 hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297:1 (2009), R111–5.
48. Arakawa, H., Chitravanshi, V.C., Sapru, H.N., The hypothalamic arcuate nucleus: a new site of cardiovascular action of angiotensin-(1–12) and angiotensin II. Am. J. Physiol. Heart Circ. Physiol. 300:3 (2011), H951–60.
49. Ferrario, C.M., Varagic, J., Habibi, J., Nagata, S., Kato, J., Chappell, M.C., Trask, A.J., Kitamura, K., Whaley-Connell, A., Sowers, J.R., Differential regulation of angiotensin-(1–12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am. J. Physiol. Heart Circ. Physiol. 296:4 (2009), H1184–92.
50. Ahmad, S., Simmons, T., Varagic, J., Moniwa, N., Chappell, M.C., Ferrario, C.M., Chymase-dependent generation of angiotensin II from angiotensin-(1–12) in human atrial tissue. PLoS One, 6(12), 2011, e28501.
51. Ahmad, S., Wei, C.C., Tallaj, J., Dell'Italia, L.J., Moniwa, N., Varagic, J., Ferrario, C.M., Chymase mediates angiotensin-(1–12) metabolism in normal human hearts. J Am Soc Hypertens 7:2 (2013), 128–136.
52. Husain, A., The chymase-angiotensin system in humans. J. Hypertens. 11:11 (1993), 1155–1159.
53. Biollaz, J., Brunner, H.R., Gavras, I., Waeber, B., Gavras, H., Antihypertensive therapy with MK 421: angiotensin II–renin relationships to evaluate efficacy of converting enzyme blockade. J. Cardiovasc. Pharmacol. 4:6 (1982), 966–972.
54. Roig, E., Perez-Villa, F., Morales, M., Jimenez, W., Orus, J., Heras, M., Sanz, G., Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur. Heart J. 21:1 (2000), 53–57.
55. Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., Breitbart, R.E., Acton, S., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ. Res. 87:5 (2000), E1–9.
56. Rice, G.I., Thomas, D.A., Grant, P.J., Turner, A.J., Hooper, N.M., Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem. J. 383:Pt 1 (2004), 45–51.
57. Turner, A.J., Tipnis, S.R., Guy, J.L., Rice, G., Hooper, N.M., ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can. J. Physiol. Pharmacol. 80:4 (2002), 346–353.
58. Ocaranza, M.P., Michea, L., Chiong, M., Lagos, C.F., Lavandero, S., Jalil, J.E., Recent insights and therapeutic perspectives of angiotensin-(1–9) in the cardiovascular system. Clin Sci (Lond) 127:9 (2014), 549–557.
59. Ferrario, C.M., Angiotensin-converting enzyme 2 and angiotensin-(1–7): an evolving story in cardiovascular regulation. Hypertension 47:3 (2006), 515–521.
60. Schiavone, M.T., Santos, R.A., Brosnihan, K.B., Khosla, M.C., Ferrario, C.M., Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1–7) heptapeptide. Proc. Natl. Acad. Sci. U. S. A. 85:11 (1988), 4095–4098.
61. Ferrario, C.M., New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension 55:2 (2010), 445–452.
62. Yamamoto, K., Chappell, M.C., Brosnihan, K.B., Ferrario, C.M., In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 19:6 Pt 2 (1992), 692–696.
63. Welches, W.R., Brosnihan, K.B., Ferrario, C.M., A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci. 52:18 (1993), 1461–1480.
64. Welches, W.R., Santos, R.A., Chappell, M.C., Brosnihan, K.B., Greene, L.J., Ferrario, C.M., Evidence that prolyl endopeptidase participates in the processing of brain angiotensin. J. Hypertens. 9:7 (1991), 631–638.
65. Ferrario, C.M., Martell, N., Yunis, C., Flack, J.M., Chappell, M.C., Brosnihan, K.B., Dean, R.H., Fernandez, A., Novikov, S.V., Pinillas, C., Luque, M., Characterization of angiotensin-(1–7) in the urine of normal and essential hypertensive subjects. Am. J. Hypertens. 11:2 (1998), 137–146.
66. Luque, M., Martin, P., Martell, N., Fernandez, C., Brosnihan, K.B., Ferrario, C.M., Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension. J. Hypertens. 14:6 (1996), 799–805.
67. de Gasparo, M., Catt, K.J., Inagami, T., Wright, J.W., Unger, T., International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52:3 (2000), 415–472.
68. Kambayashi, Y., Bardhan, S., Takahashi, K., Tsuzuki, S., Inui, H., Hamakubo, T., Inagami, T., Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. 268:33 (1993), 24543–24546.
69. Mukoyama, M., Nakajima, M., Horiuchi, M., Sasamura, H., Pratt, R.E., Dzau, V.J., Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. 268:33 (1993), 24539–24542.
70. Nakajima, M., Mukoyama, M., Pratt, R.E., Horiuchi, M., Dzau, V.J., Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor. Biochem. Biophys. Res. Commun. 197:2 (1993), 393–399.
71. Santos, R.A., Simoes e Silva, A.C., Maric, C., Silva, D.M., Machado, R.P., de Buhr, I., Heringer-Walther, S., Pinheiro, S.V., Lopes, M.T., Bader, M., Mendes, E.P., Lemos, V.S., Campagnole-Santos, M.J., Schultheiss, H.P., Speth, R., Walther, T., Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U. S. A. 100:14 (2003), 8258–8263.
72. Tetzner, A., Gebolys, K., Meinert, C., Klein, S., Uhlich, A., Trebicka, J., Villacanas, O., Walther, T., G-protein-coupled receptor MrgD is a receptor for angiotensin-(1–7) involving adenylyl cyclase, cAMP, and phosphokinase a. Hypertension 68:1 (2016), 185–194.
73. Li, P., Ferrario, C.M., Brosnihan, K.B., Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries. J. Pharmacol. Exp. Ther. 281:3 (1997), 1065–1070.
74. Li, P., Ferrario, C.M., Brosnihan, K.B., Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 32:2 (1998), 198–205.
75. Fukuhara, M., Neves, L.A., Li, P., Diz, D.I., Ferrario, C.M., Brosnihan, K.B., The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo. J. Hypertens. 19:3 Pt 2 (2001), 561–566.
76. Li, P., Fukuhara, M., Diz, D.I., Ferrario, C.M., Brosnihan, K.B., Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J. Pharmacol. Exp. Ther. 292:1 (2000), 238–246.
77. Goyal, S.N., Bharti, S., Bhatia, J., Nag, T.C., Ray, R., Arya, D.S., A dual ARB/partial PPAR-gamma agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes. Diabetes Obes. Metab. 13:6 (2011), 533–541.
78. Chida, R., Hisauchi, I., Toyoda, S., Kikuchi, M., Komatsu, T., Hori, Y., Nakahara, S., Sakai, Y., Inoue, T., Taguchi, I., Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients. Hypertens. Res. 38:11 (2015), 765–769.
79. Ferrario, C., Abdelhamed, A.I., Moore, M., AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan. Curr. Med. Res. Opin. 20:3 (2004), 279–293.
80. Wolff, M.L., Cruz, J.L., Vanderman, A.J., Brown, J.N., The effect of angiotensin II receptor blockers on hyperuricemia. Ther. Adv. Chronic Dis. 6:6 (2015), 339–346.
81. Guo, D.F., Sun, Y.L., Hamet, P., Inagami, T., The angiotensin II type 1 receptor and receptor-associated proteins. Cell Res. 11:3 (2001), 165–180.
82. Carey, R.M., Wang, Z.Q., Siragy, H.M., Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 35:1 Pt 2 (2000), 155–163.
83. Gallagher, P.E., Ferrario, C.M., Tallant, E.A., MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am. J. Physiol. Cell Physiol. 295:5 (2008), C1169–74.
84. Tallant, E.A., Ferrario, C.M., Gallagher, P.E., Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am. J. Physiol. Heart Circ. Physiol. 289:4 (2005), H1560–6.
85. Zhang, X., Cheng, H.J., Zhou, P., Kitzman, D.W., Ferrario, C.M., Li, W.M., Cheng, C.P., Cellular basis of angiotensin-(-induced augmentation of left ventricular functional performance in heart failure. Int. J. Cardiol., 2017, 1–7.
86. Calhoun, D., Sy 14-3 primary aldosteronism in resistant hypertension. J. Hypertens., 34, 2016, e369 Suppl 1 – ISH 2016 Abstract Book.
87. Calhoun, D.A., Use of aldosterone antagonists in resistant hypertension. Prog. Cardiovasc. Dis. 48:6 (2006), 387–396.
88. Clark, D. 3rd, Guichard, J.L., Calhoun, D.A., Ahmed, M.I., Recent advancements in the treatment of resistant hypertension. Postgrad. Med. 124:1 (2012), 67–73.
89. Passos-Silva, D.G., Brandan, E., Santos, R.A., Angiotensins as therapeutic targets beyond heart disease. Trends Pharmacol. Sci. 36:5 (2015), 310–320.
90. Azizi, M., Chatellier, G., Guyene, T.T., Murieta-Geoffroy, D., Menard, J., Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 92:4 (1995), 825–834.
91. Azizi, M., Menard, J., Bissery, A., Guyenne, T.T., Bura-Riviere, A., Vaidyanathan, S., Camisasca, R.P., Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol.: JASN 15:12 (2004), 3126–3133.
92. Ferrario, C.M., Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control. Life Sci. 86:9–10 (2010), 289–299.
93. Kim, S., Yoshiyama, M., Izumi, Y., Kawano, H., Kimoto, M., Zhan, Y., Iwao, H., Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 103:1 (2001), 148–154.
94. Investigators, O., Yusuf, S., Teo, K.K., Pogue, J., Dyal, L., Copland, I., Schumacher, H., Dagenais, G., Sleight, P., Anderson, C., Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358:15 (2008), 1547–1559.
95. Mancia, G., Schumacher, H., Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials. Patient Prefer Adherence 6 (2012), 1–9.
96. Yusuf, S., Teo, K.K., Pogue, J., Dyal, L., Copland, I., Schumacher, H., Dagenais, G., Sleight, P., Anderson, C., for the Ontarget Investigators, Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358:15 (2008), 1547–1559.
97. Doran, D.E., Weiss, D., Zhang, Y., Griendling, K.K., Taylor, W.R., Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species. Atherosclerosis 195:1 (2007), 39–47.
98. Stumpe, K.O., Agabiti-Rosei, E., Zielinski, T., Schremmer, D., Scholze, J., Laeis, P., Schwandt, P., Ludwig, M., M.s. investigators, Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther. Adv. Cardiovasc. Dis. 1:2 (2007), 97–106.
99. Ishii, H., Kobayashi, M., Kurebayashi, N., Yoshikawa, D., Suzuki, S., Ichimiya, S., Kanashiro, M., Sone, T., Tsuboi, H., Amano, T., Uetani, T., Harada, K., Marui, N., Murohara, T., Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris. Am. J. Cardiol. 112:3 (2013), 363–368.
100. Ferrario, C.M., Varagic, J., The ANG-(1–7)/ACE2/mas axis in the regulation of nephron function. Am. J. Physiol. Renal Physiol. 298:6 (2010), F1297–F1305.
101. Blood Pressure Lowering Treatment Trialists, C., Turnbull, F., Neal, B., Ninomiya, T., Algert, C., Arima, H., Barzi, F., Bulpitt, C., Chalmers, J., Fagard, R., Gleason, A., Heritier, S., Li, N., Perkovic, V., Woodward, M., MacMahon, S., Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336:7653 (2008), 1121–1123.
102. Aoyagi, T., Kunimoto, S., Morishima, H., Takeuchi, T., Umezawa, H., Effect of pepstatin on acid proteases. J. Antibiot. 24:10 (1971), 687–694.
103. Staessen, J.A., Li, Y., Richart, T., Oral renin inhibitors. Lancet 368:9545 (2006), 1449–1456.
104. Webb, D.J., Manhem, P.J., Ball, S.G., Inglis, G., Leckie, B.J., Lever, A.F., Morton, J.J., Robertson, J.I., Murray, G.D., Menard, J., et al. A study of the renin inhibitor H142 in man. J. Hypertens. 3:6 (1985), 653–658.
105. Pool, J.L., Direct renin inhibition: focus on aliskiren. J. Managed Care Pharm.: JMCP 13:8 Suppl B (2007), 21–33.
106. Wood, J.M., Maibaum, J., Rahuel, J., Grutter, M.G., Cohen, N.C., Rasetti, V., Ruger, H., Goschke, R., Stutz, S., Fuhrer, W., Schilling, W., Rigollier, P., Yamaguchi, Y., Cumin, F., Baum, H.P., Schnell, C.R., Herold, P., Mah, R., Jensen, C., O'Brien, E., Stanton, A., Bedigian, M.P., Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 308:4 (2003), 698–705.
107. Brown, M.J., Aliskiren. Circulation 118:7 (2008), 773–784.
108. Nobakht, N., Kamgar, M., Rastogi, A., Schrier, R.W., Limitations of angiotensin inhibition. Nat. Rev. Nephrol. 7:6 (2011), 356–359.
109. Bomback, A.S., Klemmer, P.J., The incidence and implications of aldosterone breakthrough. Nat. Clin. Pract. Nephrol. 3:9 (2007), 486–492.
110. Cicoira, M., Zanolla, L., Rossi, A., Golia, G., Franceschini, L., Cabrini, G., Bonizzato, A., Graziani, M., Anker, S.D., Coats, A.J., Zardini, P., Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J. Am. Coll. Cardiol. 37:7 (2001), 1808–1812.
111. Moranne, O., Bakris, G., Fafin, C., Favre, G., Pradier, C., Esnault, V.L., Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin. J. Am. Soc. Nephrol. 8:10 (2013), 1694–1701.
112. Mazzocchi, G., Gottardo, G., Macchi, V., Malendowicz, L.K., Nussdorfer, G.G., The AT2 receptor-mediated stimulation of adrenal catecholamine release may potentiate the AT1 receptor-mediated aldosterone secretagogue action of angiotensin-II in rats. Endocr. Res. 24:1 (1998), 17–28.
113. Naruse, M., Tanabe, A., Sato, A., Takagi, S., Tsuchiya, K., Imaki, T., Takano, K., Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 40:1 (2002), 28–33.
114. Yatabe, J., Yoneda, M., Yatabe, M.S., Watanabe, T., Felder, R.A., Jose, P.A., Sanada, H., Angiotensin III stimulates aldosterone secretion from adrenal gland partially via angiotensin II type 2 receptor but not angiotensin II type 1 receptor. Endocrinology 152:4 (2011), 1582–1588.
115. Kehoe, B., Keeton, G.R., Hill, C., Elevated plasma renin activity associated with renal dysfunction. Nephron 44:1 (1986), 51–57.
116. Malmqvist, K., Ohman, K.P., Lind, L., Nystrom, F., Kahan, T., Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J. Intern. Med. 252:5 (2002), 430–439.
117. Alderman, M.H., Ooi, W.L., Cohen, H., Madhavan, S., Sealey, J.E., Laragh, J.H., Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am. J. Hypertens. 10:1 (1997), 1–8.
118. O'Brien, E., Barton, J., Nussberger, J., Mulcahy, D., Jensen, C., Dicker, P., Stanton, A., Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 49:2 (2007), 276–284.
119. Oparil, S., Schmieder, R.E., New approaches in the treatment of hypertension. Circ. Res. 116:6 (2015), 1074–1095.
120. Menard, J., Campbell, D.J., Azizi, M., Gonzales, M.F., Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 96:9 (1997), 3072–3078.
121. Stanton, A., Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am. J. Cardiovasc. Drugs: Drugs Devices Other Interventions 3:6 (2003), 389–394.
122. Urata, H., Healy, B., Stewart, R.W., Bumpus, F.M., Husain, A., Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res. 66:4 (1990), 883–890.
123. Dzau, V.J., Bernstein, K., Celermajer, D., Cohen, J., Dahlof, B., Deanfield, J., Diez, J., Drexler, H., Ferrari, R., Van Gilst, W., Hansson, L., Hornig, B., Husain, A., Johnston, C., Lazar, H., Lonn, E., Luscher, T., Mancini, J., Mimran, A., Pepine, C., Rabelink, T., Remme, W., Ruilope, L., Ruzicka, M., Schunkert, H., Swedberg, K., Unger, T., Vaughan, D., Weber, M., Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc. Drugs Ther. 16:2 (2002), 149–160.
124. McMurray, J.J., Krum, H., Abraham, W.T., Dickstein, K., Kober, L.V., Desai, A.S., Solomon, S.D., Greenlaw, N., Ali, M.A., Chiang, Y., Shao, Q., Tarnesby, G., Massie, B.M., Enalapril, or aliskiren and enalapril in heart failure. N. Engl. J. Med. 374:16 (2016), 1521–1532.
125. Parving, H.H., Brenner, B.M., McMurray, J.J., de Zeeuw, D., Haffner, S.M., Solomon, S.D., Chaturvedi, N., Persson, F., Desai, A.S., Nicolaides, M., Richard, A., Xiang, Z., Brunel, P., Pfeffer, M.A., Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367:23 (2012), 2204–2213.
126. Gheorghiade, M., Bohm, M., Greene, S.J., Fonarow, G.C., Lewis, E.F., Zannad, F., Solomon, S.D., Baschiera, F., Botha, J., Hua, T.A., Gimpelewicz, C.R., Jaumont, X., Lesogor, A., Maggioni, A.P., Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309:11 (2013), 1125–1135.
127. Moniwa, N., Varagic, J., Ahmad, S., VonCannon, J.L., Simington, S.W., Wang, H., Groban, L., Brosnihan, K.B., Nagata, S., Kato, J., Kitamura, K., Gomez, R.A., Lopez, M.L., Ferrario, C.M., Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension. Hypertension 61:2 (2013), 417–424.
128. Rajagopalan, S., Bakris, G.L., Abraham, W.T., Pitt, B., Brook, R.D., Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies. Hypertension 62:3 (2013), 444–449.
129. Feldman, D.L., Jin, L., Xuan, H., Contrepas, A., Zhou, Y., Webb, R.L., Mueller, D.N., Feldt, S., Cumin, F., Maniara, W., Persohn, E., Schuetz, H., Jan Danser, A.H., Nguyen, G., Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52:1 (2008), 130–136.
130. Lange, S., Fraune, C., Alenina, N., Bader, M., Danser, A.H., Frenay, A.R., van Goor, H., Stahl, R., Nguyen, G., Schwedhelm, E., Wenzel, U.O., Aliskiren accumulation in the kidney: no major role for binding to renin or prorenin. J. Hypertens. 31:4 (2013), 713–719.
131. Te Riet, L., van Esch, J.H., Roks, A.J., van den Meiracker, A.H., Danser, A.H., Hypertension: renin-angiotensin-aldosterone system alterations. Circ. Res. 116:6 (2015), 960–975.
132. Balcarek, J., Seva Pessoa, B., Bryson, C., Azizi, M., Menard, J., Garrelds, I.M., McGeehan, G., Reeves, R.A., Griffith, S.G., Danser, A.H., Gregg, R., Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition. Hypertension 63:5 (2014), 942–950.
133. Ramkumar, N., Kohan, D.E., Proximal tubule angiotensinogen modulation of arterial pressure. Curr. Opin. Nephrol. Hypertens. 22:1 (2013), 32–36.
134. Schnermann, J., Levine, D.Z., Paracrine factors in tubuloglomerular feedback: adenosine, ATP, and nitric oxide. Annu. Rev. Physiol. 65 (2003), 501–529.
135. Burke, M., Pabbidi, M.R., Farley, J., Roman, R.J., Molecular mechanisms of renal blood flow autoregulation. Curr. Vasc. Pharmacol. 12:6 (2014), 845–858.
136. Rohrwasser, A., Morgan, T., Dillon, H.F., Zhao, L., Callaway, C.W., Hillas, E., Zhang, S., Cheng, T., Inagami, T., Ward, K., Terreros, D.A., Lalouel, J.M., Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension 34:6 (1999), 1265–1274.
137. Navis, G., Faber, H.J., de Zeeuw, D., de Jong, P.E., ACE inhibitors and the kidney. A risk-benefit assessment. Drug Saf. 15:3 (1996), 200–211.
138. Griffiths, C.D., Morgan, T.O., Delbridge, L.M., Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high NaCl intake. J. Hypertens. 19:11 (2001), 2087–2095.
139. Richer-Giudicelli, C., Domergue, V., Gonzalez, M.F., Messadi, E., Azizi, M., Giudicelli, J.F., Menard, J., Haemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats: influence of salt. J. Hypertens. 22:3 (2004), 619–627.
140. Sealey, J.E., Alderman, M.H., Furberg, C.D., Laragh, J.H., Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels. Am. J. Hypertens. 26:6 (2013), 727–738.
141. Turgut, F., Balogun, R.A., Abdel-Rahman, E.M., Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations. Clin. J. Am. Soc. Nephrol.: CJASN 5:7 (2010), 1330–1339.
142. Schoolwerth, A.C., Sica, D.A., Ballermann, B.J., Wilcox, C.S., Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104:16 (2001), 1985–1991.
143. Bicket, D.P., Using ACE inhibitors appropriately. Am. Fam. Physician 66:3 (2002), 461–468.
144. Gohlke, P., Scholkens, B.A., Inhibitors, A.C.E., Pharmacology. Unger, T., Scholkens, B.A., (eds.) Angiotensin, 2004, Springer – Verlag, Berlin, 375–413.
145. Davis, R., Coukell, A., McTavish, D., A review of its pharmacology and clinical efficacy in the management of heart failure. Drugs 54:1 (1997), 103–116.
146. White, C.M., Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 18:3 (1998), 588–599.
147. Wong, M.C., Chan, D.K., Wang, H.H., Tam, W.W., Cheung, C.S., Yan, B.P., Coats, A.J., The incidence of all-cause, cardiovascular and respiratory disease admission among 20,252 users of lisinopril vs. perindopril: a cohort study. Int. J. Cardiol. 219 (2016), 410–416.
148. Juillerat, L., Nussberger, J., Menard, J., Mooser, V., Christen, Y., Waeber, B., Graf, P., Brunner, H.R., Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 16:5 (1990), 564–572.
149. Wei, C.C., Tian, B., Perry, G., Meng, Q.C., Chen, Y.F., Oparil, S., Dell'Italia, L.J., Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene. Am. J. Physiol. Heart Circ. Physiol. 282:6 (2002), H2254–8.
150. Ahmad, S., Varagic, J., Westwood, B.M., Chappell, M.C., Ferrario, C.M., Uptake and metabolism of the novel peptide angiotensin-(1–12) by neonatal cardiac myocytes. PLoS One, 6(1), 2011, e15759.
151. Husain, A., Li, M., Graham, R.M., Do studies with ACE N- and C-domain-selective inhibitors provide evidence for a non-ACE, non-chymase angiotensin II-forming pathway?. Circ. Res. 93:2 (2003), 91–93.
152. Dive, V., Cotton, J., Yiotakis, A., Michaud, A., Vassiliou, S., Jiracek, J., Vazeux, G., Chauvet, M.T., Cuniasse, P., Corvol, P., RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc. Natl. Acad. Sci. U. S. A. 96:8 (1999), 4330–4335.
153. van Vark, L.C., Bertrand, M., Akkerhuis, K.M., Brugts, J.J., Fox, K., Mourad, J.J., Boersma, E., Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur. Heart J. 33:16 (2012), 2088–2097.
154. Zanchetti, A., Thomopoulos, C., Parati, G., Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circ. Res. 116:6 (2015), 1058–1073.
155. Miura, S., Fujino, M., Hanzawa, H., Kiya, Y., Imaizumi, S., Matsuo, Y., Tomita, S., Uehara, Y., Karnik, S.S., Yanagisawa, H., Koike, H., Komuro, I., Saku, K., Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J. Biol. Chem. 281:28 (2006), 19288–19295.
156. Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., Remuzzi, G., Snapinn, S.M., Zhang, Z., Shahinfar, S., Investigators, R.S., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345:12 (2001), 861–869.
157. Dahlof, B., Devereux, R.B., Kjeldsen, S.E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L.H., Nieminen, M.S., Omvik, P., Oparil, S., Wedel, H., for the LIFE Study Group, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:9311 (2002), 995–1003.
158. Konstam, M.A., Neaton, J.D., Dickstein, K., Drexler, H., Komajda, M., Martinez, F.A., Riegger, G.A., Malbecq, W., Smith, R.D., Guptha, S., Poole-Wilson, P.A., for the Heaal Investigator, s., Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374:9704 (2009), 1840–1848.
159. Cohn, J.N., Tognoni, G., for the Valsartan Heart Failure Trial Investigators, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345:23 (2001), 1667–1675.
160. Group, T.N.S., McMurray, J.J., Holman, R.R., Haffner, S.M., Bethel, M.A., Holzhauer, B., Hua, T.A., Belenkov, Y., Boolell, M., Buse, J.B., Buckley, B.M., Chacra, A.R., Chiang, F.T., Charbonnel, B., Chow, C.C., Davies, M.J., Deedwania, P., Diem, P., Einhorn, D., Fonseca, V., Fulcher, G.R., Gaciong, Z., Gaztambide, S., Giles, T., Horton, E., Ilkova, H., Jenssen, T., Kahn, S.E., Krum, H., Laakso, M., Leiter, L.A., Levitt, N.S., Mareev, V., Martinez, F., Masson, C., Mazzone, T., Meaney, E., Nesto, R., Pan, C., Prager, R., Raptis, S.A., Rutten, G.E., Sandstroem, H., Schaper, F., Scheen, A., Schmitz, O., Sinay, I., Soska, V., Stender, S., Tamas, G., Tognoni, G., Tuomilehto, J., Villamil, A.S., Vozar, J., Califf, R.M., Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362:16 (2010), 1477–1490.
161. Julius, S., Kjeldsen, S.E., Brunner, H., Hansson, L., Platt, F., Ekman, S., Laragh, J.H., McInnes, G., Schork, A.M., Smith, B., Weber, M., Zanchetti, A., VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am. J. Hypertens. 16:7 (2003), 544–548.
162. Julius, S., Nesbitt, S.D., Egan, B.M., Weber, M.A., Michelson, E.L., Kaciroti, N., Black, H.R., Grimm, R.H. Jr., Messerli, F.H., Oparil, S., Schork, M.A., for the Trial of Preventing Hypertension Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med. 354:16 (2006), 1685–1697.
163. Pfeffer, M.A., McMurray, J.J., Velazquez, E.J., Rouleau, J.L., Kober, L., Maggioni, A.P., Solomon, S.D., Swedberg, K., Van de Werf, F., White, H., Leimberger, J.D., Henis, M., Edwards, S., Zelenkofske, S., Sellers, M.A., Califf, R.M., for the Valsartan in Acute Myocardial Infarction Trial Investigators, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349:20 (2003), 1893–1906.
164. Granger, C.B., McMurray, J.J., Yusuf, S., Held, P., Michelson, E.L., Olofsson, B., Ostergren, J., Pfeffer, M.A., Swedberg, K., for the CHARM Investigators and Committees, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:9386 (2003), 772–776.
165. McMurray, J.J., Ostergren, J., Swedberg, K., Granger, C.B., Held, P., Michelson, E.L., Olofsson, B., Yusuf, S., Pfeffer, M.A., for the CHARM Investigators and Committees, Committees, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362:9386 (2003), 767–771.
166. Pfeffer, M.A., Swedberg, K., Granger, C.B., Held, P., McMurray, J.J., Michelson, E.L., Olofsson, B., Ostergren, J., Yusuf, S., Pocock, S., Investigators, C., Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 362:9386 (2003), 759–766.
167. Yusuf, S., Pfeffer, M.A., Swedberg, K., Granger, C.B., Held, P., McMurray, J.J., Michelson, E.L., Olofsson, B., Ostergren, J., Investigators, C., Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 362:9386 (2003), 777–781.
168. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., Ritz, E., Atkins, R.C., Rohde, R., Raz, I., Collaborative Study, G., Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345:12 (2001), 851–860.
169. Massie, B.M., Carson, P.E., McMurray, J.J., Komajda, M., McKelvie, R., Zile, M.R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., Ptaszynska, A., Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 359:23 (2008), 2456–2467.
170. Ritz, E., Viberti, G.C., Ruilope, L.M., Rabelink, A.J., Izzo, J.L. Jr., Katayama, S., Ito, S., Mimran, A., Menne, J., Rump, L.C., Januszewicz, A., Haller, H., Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 53:1 (2010), 49–57.
171. Dusing, R., Pharmacological interventions into the renin-angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering. Ther. Adv. Cardiovasc. Dis. 10:3 (2016), 151–161.
172. Ruschitzka, F., Taddei, S., Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection?. Eur. Heart J. 33:16 (2012), 1996–1998.
173. Kumar, R., Thomas, C.M., Yong, Q.C., Chen, W., Baker, K.M., The intracrine renin-angiotensin system. Clin. Sci. (Lond.) 123:5 (2012), 273–284.
174. Re, R.N., Cardiac angiotensin II: an intracrine hormone?. Am. J. Hypertens. 16:5 Pt 1 (2003), 426–427.
175. Re, R.N., Cook, J.L., Noncanonical intracrine action. J. Am. Soc. Hypertens. 5:6 (2011), 435–448.
176. Grundy, H.M., Simpson, S.A., Tait, J.F., Isolation of a highly active mineralocorticoid from beef adrenal extract. Nature 169:4306 (1952), 795–796.
177. Tait, J.F., Simpson, S.A., Grundy, H.M., The effect of adrenal extract on mineral metabolism. Lancet 1:6699 (1952), 122–124.
178. Cranston, W.I., Juel-Jensen, B.E., The effects of spironolactone and chlorthalidone on arterial pressure. Lancet 1:7240 (1962), 1161–1164.
179. Conn, J.W., Primary aldosteronism. J. Lab. Clin. Med. 45:4 (1955), 661–664.
180. Judd, E., Calhoun, D.A., Management of resistant hypertension: do not give up on medication. Nephrol. Self Assess. Program 13:2 (2014), 57–63.
181. Gomez-Sanchez, C.E., Non renal effects of aldosterone. Steroids 91 (2014), 1–2.
182. Pitt, B., Kober, L., Ponikowski, P., Gheorghiade, M., Filippatos, G., Krum, H., Nowack, C., Kolkhof, P., Kim, S.Y., Zannad, F., Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 34:31 (2013), 2453–2463.
183. Liu, L.C., Schutte, E., Gansevoort, R.T., van der Meer, P., Voors, A.A., Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin. Investig. Drugs 24:8 (2015), 1123–1135.
184. Filippatos, G., Anker, S.D., Bohm, M., Gheorghiade, M., Kober, L., Krum, H., Maggioni, A.P., Ponikowski, P., Voors, A.A., Zannad, F., Kim, S.Y., Nowack, C., Palombo, G., Kolkhof, P., Kimmeskamp-Kirschbaum, N., Pieper, A., Pitt, B., A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur. Heart J. 37:27 (2016), 2105–2114.
185. Barfacker, L., Kuhl, A., Hillisch, A., Grosser, R., Figueroa-Perez, S., Heckroth, H., Nitsche, A., Erguden, J.K., Gielen-Haertwig, H., Schlemmer, K.H., Mittendorf, J., Paulsen, H., Platzek, J., Kolkhof, P., Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7:8 (2012), 1385–1403.
186. Fleseriu, M., Castinetti, F., Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies. Pituitary 19:6 (2016), 643–653.
187. Fleseriu, M., Pivonello, R., Young, J., Hamrahian, A.H., Molitch, M.E., Shimizu, C., Tanaka, T., Shimatsu, A., White, T., Hilliard, A., Tian, C., Sauter, N., Biller, B.M., Bertagna, X., a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. Pituitary 19:2 (2016), 138–148.
188. Lea, W.B., Kwak, E.S., Luther, J.M., Fowler, S.M., Wang, Z., Ma, J., Fogo, A.B., Brown, N.J., Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 75:9 (2009), 936–944.
189. Menard, J., Gonzalez, M.F., Guyene, T.T., Bissery, A., Investigation of aldosterone-synthase inhibition in rats. J. Hypertens. 24:6 (2006), 1147–1155.
190. Gu, J., Noe, A., Chandra, P., Al-Fayoumi, S., Ligueros-Saylan, M., Sarangapani, R., Maahs, S., Ksander, G., Rigel, D.F., Jeng, A.Y., Lin, T.H., Zheng, W., Dole, W.P., Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J. Clin. Pharmacol. 50:4 (2010), 401–414.
191. Chappell, M.C., Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?. Am. J. Physiol. Heart Circ. Physiol. 310:2 (2016), H137–H152.
192. Uijl, E., Roksnoer, L.C., Hoorn, E.J., Danser, A.H., From ARB to ARNI in cardiovascular control. Curr. Hypertens. Rep., 18(12), 2016, 86.
193. Vardeny, O., Miller, R., Solomon, S.D., Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2:6 (2014), 663–670.
194. Ando, S., Rahman, M.A., Butler, G.C., Senn, B.L., Floras, J.S., Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 26:6 Pt 2 (1995), 1160–1166.
195. McDowell, G., Nicholls, D.P., The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man. Expert Opin. Investig. Drugs 8:1 (1999), 79–84.
196. Cleland, J.G., Swedberg, K., Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet 351:9116 (1998), 1657–1658.
197. Campese, V.M., Lasseter, K.C., Ferrario, C.M., Smith, W.B., Ruddy, M.C., Grim, C.E., Smith, R.D., Vargas, R., Habashy, M.F., Vesterqvist, O., Delaney, C.L., Liao, W.C., Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension 38:6 (2001), 1342–1348.
198. Ferrario, C.M., Averill, D.B., Brosnihan, K.B., Chappell, M.C., Iskandar, S.S., Dean, R.H., Diz, D.I., Vasopeptidase inhibition and Ang-(1–7) in the spontaneously hypertensive rat. Kidney Int. 62:4 (2002), 1349–1357.
199. Ferrario, C.M., Smith, R.D., Brosnihan, B., Chappell, M.C., Campese, V.M., Vesterqvist, O., Liao, W.C., Ruddy, M.C., Grim, C.E., Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am. J. Hypertens. 15:6 (2002), 557–564.
200. Eisenstein, E.L., Nelson, C.L., Simon, T.A., Smitten, A.L., Lapuerta, P., Mark, D.B., Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure. Am. Heart J. 143:6 (2002), 1112–1117.
201. Packer, M., Califf, R.M., Konstam, M.A., Krum, H., McMurray, J.J., Rouleau, J.L., Swedberg, K., Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 106:8 (2002), 920–926.
202. Pickering, T.G., Effects of stress and behavioral interventions in hypertension: the rise and fall of omapatrilat. J. Clin. Hypertens. 4:5 (2002), 371–373.
203. Ruilope, L.M., Dukat, A., Bohm, M., Lacourciere, Y., Gong, J., Lefkowitz, M.P., Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375:9722 (2010), 1255–1266.
204. Solomon, S.D., Claggett, B., McMurray, J.J., Hernandez, A.F., Fonarow, G.C., Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. Eur. J. Heart Fail. 18:10 (2016), 1238–1243.
205. Solomon, S.D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J., Lefkowitz, M., Packer, M., McMurray, J.J., Prospective comparison of, The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled triall. Lancet 380:9851 (2012), 1387–1395.
206. Kario, K., Sun, N., Chiang, F.T., Supasyndh, O., Baek, S.H., Inubushi-Molessa, A., Zhang, Y., Gotou, H., Lefkowitz, M., Zhang, J., Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension 63:4 (2014), 698–705.
207. McMurray, J.J., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., Rouleau, J.L., Shi, V.C., Solomon, S.D., Swedberg, K., Zile, M.R., P.-H. Investigators, Committees, Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371:11 (2014), 993–1004.
208. Yusuf, S., Pitt, B., Davis, C.E., Hood, W.B., Cohn, J.N., Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325:5 (1991), 293–302.
209. Feldman, A.M., Haller, J.A., DeKosky, S.T., Valsartan/sacubitril for heart failure: reconciling disparities between preclinical and clinical investigations. JAMA 315:1 (2016), 25–26.
210. Langenickel, T.H., Tsubouchi, C., Ayalasomayajula, S., Pal, P., Valentin, M.A., Hinder, M., Jhee, S., Gevorkyan, H., Rajman, I., The effect of LCZ696 (sacubitril/valsartan) on amyloid-beta concentrations in cerebrospinal fluid in healthy subjects. Br. J. Clin. Pharmacol. 81:5 (2016), 878–890.
211. Cannon, J.A., Shen, L., Jhund, P.S., Kristensen, S.L., Kober, L., Chen, F., Gong, J., Lefkowitz, M.P., Rouleau, J.L., Shi, V.C., Swedberg, K., Zile, M.R., Solomon, S.D., Packer, M., McMurray, J.J., Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur. J. Heart Fail. 19:1 (2017), 129–137.
212. Lalouel, J.M., Rohrwasser, A., Genetic susceptibility to essential hypertension: insight from angiotensinogen. Hypertension 49:3 (2007), 597–603.
213. Dickson, M.E., Sigmund, C.D., Genetic basis of hypertension: revisiting angiotensinogen. Hypertension 48:1 (2006), 14–20.
214. Zhou, A., Carrell, R.W., Murphy, M.P., Wei, Z., Yan, Y., Stanley, P.L., Stein, P.E., Broughton Pipkin, F., Read, R.J., A redox switch in angiotensinogen modulates angiotensin release. Nature 468:7320 (2010), 108–111.
215. Ward, K., Hata, A., Jeunemaitre, X., Helin, C., Nelson, L., Namikawa, C., Farrington, P.F., Ogasawara, M., Suzumori, K., Tomoda, S., et al. A molecular variant of angiotensinogen associated with preeclampsia. Nat. Genet. 4:1 (1993), 59–61.
216. Corvol, P., Jeunemaitre, X., Molecular genetics of human hypertension: role of angiotensinogen. Endocr. Rev. 18:5 (1997), 662–677.
217. Kim, H.S., Krege, J.H., Kluckman, K.D., Hagaman, J.R., Hodgin, J.B., Best, C.F., Jennette, J.C., Coffman, T.M., Maeda, N., Smithies, O., Genetic control of blood pressure and the angiotensinogen locus. Proc. Natl. Acad. Sci. U. S. A. 92:7 (1995), 2735–2739.
218. Phillips, M.I., Wielbo, D., Gyurko, R., Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes. Kidney Int. 46:6 (1994), 1554–1556.
219. Gyurko, R., Wielbo, D., Phillips, M.I., Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul. Pept. 49:2 (1993), 167–174.
220. Wielbo, D., Sernia, C., Gyurko, R., Phillips, M.I., Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension 25:3 (1995), 314–319.
221. Wielbo, D., Simon, A., Phillips, M.I., Toffolo, S., Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. Hypertension 28:1 (1996), 147–151.
222. Tomita, N., Morishita, R., Higaki, J., Aoki, M., Nakamura, Y., Mikami, H., Fukamizu, A., Murakami, K., Kaneda, Y., Ogihara, T., Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 26:1 (1995), 131–136.
223. Sugano, M., Tsuchida, K., Sawada, S., Makino, N., Reduction of plasma angiotensin II to normal levels by antisense oligodeoxynucleotides against liver angiotensinogen cannot completely attenuate vascular remodeling in spontaneously hypertensive rats. J. Hypertens. 18:6 (2000), 725–731.
224. Makino, N., Sugano, M., Ohtsuka, S., Sawada, S., Hata, T., Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats. Cardiovasc. Res. 44:3 (1999), 543–548.
225. Makino, N., Sugano, M., Ohtsuka, S., Sawada, S., Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension 31:5 (1998), 1166–1170.
226. Tang, X., Mohuczy, D., Zhang, Y.C., Kimura, B., Galli, S.M., Phillips, M.I., Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension. Am. J. Physiol. 277:6 Pt 2 (1999), H2392–9.
227. Boiziau, C., Kurfurst, R., Cazenave, C., Roig, V., Thuong, N.T., Toulme, J.J., Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism. Nucleic Acids Res. 19:5 (1991), 1113–1119.
228. Kole, R., Krainer, A.R., Altman, S., RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 11:2 (2012), 125–140.
229. Bennett, C.F., Swayze, E.E., RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacool. Toxicol. 50 (2010), 259–293.
230. Lu, H., Wu, C., Howatt, D.A., Balakrishnan, A., Moorleghen, J.J., Chen, X., Zhao, M., Graham, M.J., Mullick, A.E., Crooke, R.M., Feldman, D.L., Cassis, L.A., Vander Kooi, C.W., Daugherty, A., Angiotensinogen exerts effects independent of angiotensin II. Arterioscler. Thromb. Vasc. Biol. 36:2 (2016), 256–265.
231. Ravichandran, K., Ozkok, A., Wang, Q., Mullick, A.E., Edelstein, C.L., Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2. Am. J. Physiol. Renal Physiol. 308:4 (2015), F349–F357.
232. Saigusa, T., Dang, Y., Mullick, A.E., Yeh, S.T., Zile, M.R., Baicu, C.F., Bell, P.D., Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model. FASEB J.: Off. Publ. Federation Am. Soc. Exp. Biol. 30:1 (2016), 370–379.
233. Olearczyk, J., Gao, S., Eybye, M., Yendluri, S., Andrews, L., Bartz, S., Cully, D., Tadin-Strapps, M., Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension. Hypertens. Res.: Off. J. Jpn. Soc. Hypertens. 37:5 (2014), 405–412.
234. Haase, N., Foster, D., Bercher, J., Milstein, S., Golic, M., Charisse, K., Rugor, J., Kuchimanchi, S., Przybyl, L., Bettencourt, B., Müller, D.N., Hinkle, G., Dechend, R., RNAi therapeutics targeting human angiotensinogen (hAGT) ameliorate preeclamptic sequelae in an established transgenic rodent model for preeclampsia. Hypertension, 64, 2014 Abstract 666.
235. Mullick, A.E., Yeh, S.T., Graham, M.J., Crooke, R.M., Liver-specific antisense inhibition of angiotensinogen reduced BP in a hypertensive rat model resistant to standard RAS inhibition. Hypertension, 66(Suppl. 1), 2015 Abstract P605.
236. Mullick, A.E., Brown, H.L., Graham, M.J., Crooke, R.M., Antisense inhibition of angiotensinogen reduces BP in normotensive sprague-dawley rats and effectively eliminates RAS-dependent BP control In hypertensive SHR rats. Hypertension, 60, 2012 Abstract 627.
237. Crackower, M.A., Sarao, R., Oudit, G.Y., Yagil, C., Kozieradzki, I., Scanga, S.E., Oliveira-dos-Santos, A.J., da Costa, J., Zhang, L., Pei, Y., Scholey, J., Ferrario, C.M., Manoukian, A.S., Chappell, M.C., Backx, P.H., Yagil, Y., Penninger, J.M., Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417:6891 (2002), 822–828.
238. Turner, A.J., Hiscox, J.A., Hooper, N.M., ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol. Sci. 25:6 (2004), 291–294.
239. Carey, R.M., Padia, S.H., Role of angiotensin AT(2) receptors in natriuresis: intrarenal mechanisms and therapeutic potential. Clin. Exp. Pharmacol. Physiol. 40:8 (2013), 527–534.
240. Chow, B.S., Allen, T.J., Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease. Clin. Sci. (Lond.) 130:15 (2016), 1307–1326.
241. Menk, M., Graw, J.A., von Haefen, C., Sifringer, M., Schwaiberger, D., Unger, T., Steckelings, U., Spies, C.D., Stimulation of the angiotensin II AT2 receptor is anti-inflammatory in human lipopolysaccharide-activated monocytic cells. Inflammation 38:4 (2015), 1690–1699.
242. Kemp, B.A., Howell, N.L., Gildea, J.J., Keller, S.R., Padia, S.H., Carey, R.M., AT(2) receptor activation induces natriuresis and lowers blood pressure. Circ. Res. 115:3 (2014), 388–399.
243. Sumners, C., de Kloet, A.D., Krause, E.G., Unger, T., Steckelings, U.M., Angiotensin type 2 receptors: blood pressure regulation and end organ damage. Curr. Opin. Pharmacol. 21 (2015), 115–121.
244. Tamargo, J., Duarte, J., Ruilope, L.M., New antihypertensive drugs under development. Curr. Med. Chem. 22:3 (2015), 305–342.
245. Wysocki, J., Ye, M., Rodriguez, E., Gonzalez-Pacheco, F.R., Barrios, C., Evora, K., Schuster, M., Loibner, H., Brosnihan, K.B., Ferrario, C.M., Penninger, J.M., Batlle, D., Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 55:1 (2010), 90–98.
246. Haschke, M., Schuster, M., Poglitsch, M., Loibner, H., Salzberg, M., Bruggisser, M., Penninger, J., Krahenbuhl, S., Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin. Pharmacokinet. 52:9 (2013), 783–792.
247. Machado-Silva, A., Passos-Silva, D., Santos, R.A., Sinisterra, R.D., Therapeutic uses for angiotensin-(1–7). Expert Opin. Ther. Pat. 26:6 (2016), 669–678.
248. Folkow, B., The haemodynamic consequences of adaptive structural changes of the resistance vessels in hypertension. Clin. Sci. 41:1 (1971), 1–12.
249. Folkow, B., Sivertsson, R., [Hemodynamic consequences of adaptive reconstruction of resistance vessels]. Lakartidningen 68:45 (1971), 5165–5173.
250. Smith, R.D., Yokoyama, H., Averill, D.B., Schiffrin, E.L., Ferrario, C.M., Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. J. Am. Soc. Hypertens. 2:3 (2008), 165–172.
251. Schiffrin, E.L., Vascular changes in hypertension in response to drug treatment: effects of angiotensin receptor blockers. Can. J. Cardiol. 18:Suppl. A (2002), 15A–18A.
252. Schiffrin, E.L., Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy?. Curr. Opin. Nephrol. Hypertens. 10:5 (2001), 617–624.
253. Schiffrin, E.L., Small artery remodeling in hypertension: can it be corrected?. Am. J. Med. Sci. 322:1 (2001), 7–11.
254. Abadir, P.M., Walston, J.D., Carey, R.M., Subcellular characteristics of functional intracellular renin-angiotensin systems. Peptides 38:2 (2012), 437–445.
255. Baker, K.M., Chernin, M.I., Schreiber, T., Sanghi, S., Haiderzaidi, S., Booz, G.W., Dostal, D.E., Kumar, R., Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul. Pept. 120:1–3 (2004), 5–13.
256. Kumar, R., Singh, V.P., Baker, K.M., The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol. Metab. 18:5 (2007), 208–214.
257. Re, R.N., The cellular biology of angiotensin: paracrine, autocrine and intracrine actions in cardiovascular tissues. J. Mol. Cell. Cardiol. 21 (1989), 63–69.
258. Wilson, B.A., Cruz-Diaz, N., Su, Y., Rose, J.C., Gwathmey, T.M., Chappell, M.C., Angiotensinogen import in isolated proximal tubules: evidence for mitochondrial trafficking and uptake. Am. J. Physiol. Renal Physiol., 00246, 2016 ajprenal.
259. Wang, H., Jessup, J.A., Zhao, Z., Da Silva, J., Lin, M., MacNamara, L.M., Ahmad, S., Chappell, M.C., Ferrario, C.M., Groban, L., Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2. Lewis rats. PLoS One, 8(10), 2013, e76992.
260. Alzayadneh, E.M., Chappell, M.C., Nuclear expression of renin-angiotensin system components in NRK-52E renal epithelial cells. J. Renin Angiotensin Aldosterone Syst. 16:4 (2015), 1135–1148.
261. Ferrario, C.M., Jessup, J., Chappell, M.C., Averill, D.B., Brosnihan, K.B., Tallant, E.A., Diz, D.I., Gallagher, P.E., Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111:20 (2005), 2605–2610.
262. Varagic, J., Ahmad, S., VonCannon, J.L., Moniwa, N., Brosnihan, K.B., Wysocki, J., Batlle, D., Ferrario, C.M., Predominance of AT(1) blockade over mas-mediated angiotensin-(1–7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2. Lewis rats. Am. J. Hypertens. 26:5 (2013), 583–590.
263. Urata, H., Kinoshita, A., Perez, D.M., Misono, K.S., Bumpus, F.M., Graham, R.M., Husain, A., Cloning of the gene and cDNA for human heart chymase. J. Biol. Chem. 266:26 (1991), 17173–17179.
264. Wei, C.C., Hase, N., Inoue, Y., Bradley, E.W., Yahiro, E., Li, M., Naqvi, N., Powell, P.C., Shi, K., Takahashi, Y., Saku, K., Urata, H., Dell'italia, L.J., Husain, A., Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J. Clin. Invest. 120:4 (2010), 1229–1239.
265. Jin, D., Takai, S., Okamoto, Y., Muramatsu, M., Miyazaki, M., Chymase-derived angiotensin II and arrhythmias after myocardial infarction. Nihon Yakurigaku Zasshi 124:2 (2004), 77–82.
266. Jin, D., Takai, S., Sakaguchi, M., Okamoto, Y., Muramatsu, M., Miyazaki, M., An antiarrhythmic effect of a chymase inhibitor after myocardial infarction. J. Pharmacol. Exp. Ther. 309:2 (2004), 490–497.
267. Jin, D., Takai, S., Yamada, M., Sakaguchi, M., Kamoshita, K., Ishida, K., Sukenaga, Y., Miyazaki, M., Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc. Res. 60:2 (2003), 413–420.
268. Takai, S., Jin, D., Improvement of cardiovascular remodelling by chymase inhibitor. Clin. Exp. Pharmacol. Physiol. 43:4 (2016), 387–393.
269. Takai, S., Jin, D., Miyazaki, M., Targets of chymase inhibitors. Expert Opin. Ther. Targets 15:4 (2011), 519–527.
270. Takai, S., Jin, D., Muramatsu, M., Miyazaki, M., Chymase as a novel target for the prevention of vascular diseases. Trends Pharmacol. Sci. 25:10 (2004), 518–522.
271. Takai, S., Jin, D., Muramatsu, M., Okamoto, Y., Miyazaki, M., Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis. Eur. J. Pharmacol. 501:1-3 (2004), 1–8.
272. Pitt, B., Segal, R., Martinez, F.A., Meurers, G., Cowley, A.J., Thomas, I., Deedwania, P.C., Ney, D.E., Snavely, D.B., Chang, P.I., Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:9054 (1997), 747–752.
273. Pitt, B., Poole-Wilson, P.A., Segal, R., Martinez, F.A., Dickstein, K., Camm, A.J., Konstam, M.A., Riegger, G., Klinger, G.H., Neaton, J., Sharma, D., Thiyagarajan, B., Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial–the Losartan Heart Failure Survival Study ELITE II. Lancet 355:9215 (2000), 1582–1587.
274. Yusuf, S., Teo, K., Anderson, C., Pogue, J., Dyal, L., Copland, I., Schumacher, H., Dagenais, G., Sleight, P., for the Telmisartan Randomised AssessmeNt Study in, A. C. E. iNtolerant subjects with cardiovascular Disease Investigators, Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372:9644 (2008), 1174–1183.
275. Dickstein, K., Kjekshus, J., the Optimaal Steering Committee, for the OPTIMAAL Study Group, Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360:9335 (2002), 752–760.